Evidence map›Paper›PMID 32521122›Full record

ArticleCurrent protocols in stem cell biology2020

Purification of Live Stem-Cell-Derived Islet Lineage Intermediates.

Niloofar Rasouli, Douglas A Melton, Juan R Alvarez-Dominguez

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Current protocols in stem cell biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Niloofar RasouliDepartment of Stem Cell and Regenerative Biology, Harvard Stem Cell Institute, Harvard University, Cambridge, Massachusetts.
Douglas A MeltonDepartment of Stem Cell and Regenerative Biology, Harvard Stem Cell Institute, Harvard University, Cambridge, Massachusetts.
Juan R Alvarez-DominguezDepartment of Stem Cell and Regenerative Biology, Harvard Stem Cell Institute, Harvard University, Cambridge, Massachusetts.

Funding

Production of clinical-grade diabetes patient-specific induced pluripotent stem cell lines intended for autologous beta cell replacement therapyUC4DK104165 · NIDDK · HARVARD UNIVERSITY · PI MELTON, DOUGLAS A · 2014 to 2017
$7.3M
Biomarkers for Diabetes Using Stem Cell-Derived Beta CellsUC4DK104159 · NIDDK · HARVARD UNIVERSITY · PI MELTON, DOUGLAS A · 2014 to 2014
$1.6M
NIDDK NIH HHS UC4 DK104159NIDDK NIH HHS UC4 DK104165
6 · The paper itself

Abstract

Stem-cell-derived tissues offer platforms to study organ development, model physiology during health and disease, and test novel therapies. We describe methods to isolate cells at successive stages during in vitro differentiation of human stem cells into the pancreatic endocrine lineage. Using flow cytometry, we purify live lineage intermediates in numbers not available by fetal biopsy. These include pancreatic and endocrine progenitors, isolated based on known surface markers. We further report a strategy that leverages intracellular zinc content and DPP4/CD26 expression to separate monohormonal insulin

Indexed as

BiomarkersCell DifferentiationFlow CytometryHumansInsulin-Secreting CellsStem CellsBiomarkerscell surface markersfluorescence-activated cell sortingstem-cell-derived islets

Identifiers

PMID32521122
PMCPMC7391169

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.